Cited 0 times in
Adenosine triphosphate-based chemotherapy response assay-guided chemotherapy in unresectable colorectal liver metastasis.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김남규 | - |
dc.contributor.author | 김호근 | - |
dc.contributor.author | 민병소 | - |
dc.contributor.author | 신상준 | - |
dc.contributor.author | 이강영 | - |
dc.contributor.author | 천재희 | - |
dc.contributor.author | 허혁 | - |
dc.date.accessioned | 2014-12-19T16:35:43Z | - |
dc.date.available | 2014-12-19T16:35:43Z | - |
dc.date.issued | 2012 | - |
dc.identifier.issn | 0007-0920 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/89825 | - |
dc.description.abstract | BACKGROUND: This study aims to evaluate the effectiveness of adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided neoadjuvant chemotherapy for increasing resectability in patients with unresectable colorectal liver metastasis. PATIENTS AND METHODS: Patients were randomised into two groups: Group A was treated by conventional chemotherapy regimen and Group B was treated by chemotherapy regimen according to the ATP-CRA. Three chemotherapeutic agents (5-fluorouracil, oxaliplatin and irinotecan) were tested by ATP-CRA and more sensitive agents were selected. Either FOLFOX or FOLFIRI was administered. Between Group A and B, treatment response and resectability were compared. RESULTS: Between November 2008 and October 2010, a total 63 patients were randomised to Group A (N=32) or Group B (N=31). FOLFOX was more preferred in Group A than in Group B (26 out of 32 (81.3%) vs 20 out of 31 (64.5%)). Group B showed better treatment response than Group A (48.4% vs 21.9%, P=0.027). The resectability of hepatic lesion was higher in Group B (35.5% vs 12.5%, P=0.032). Mean duration from chemotherapy onset to the time of liver resection was 11 cycles (range 4-12) in Group A and 8 cycles (range 8-16) in Group B. CONCLUSION: This study showed that tailored-chemotherapy based on ATP-CRA could improve the treatment response and resectability in initially unresectable colorectal liver metastasis. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | BRITISH JOURNAL OF CANCER | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adenosine Triphosphate/therapeutic use* | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/therapeutic use* | - |
dc.subject.MESH | Colorectal Neoplasms/drug therapy | - |
dc.subject.MESH | Colorectal Neoplasms/pathology* | - |
dc.subject.MESH | Combined Modality Therapy | - |
dc.subject.MESH | Feasibility Studies | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Liver Neoplasms/drug therapy* | - |
dc.subject.MESH | Liver Neoplasms/secondary | - |
dc.subject.MESH | Liver Neoplasms/surgery | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Adenosine triphosphate-based chemotherapy response assay-guided chemotherapy in unresectable colorectal liver metastasis. | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Pathology (병리학) | - |
dc.contributor.googleauthor | H Hur | - |
dc.contributor.googleauthor | NK Kim | - |
dc.contributor.googleauthor | HG Kim | - |
dc.contributor.googleauthor | BS Min | - |
dc.contributor.googleauthor | KY Lee | - |
dc.contributor.googleauthor | SJ Shin | - |
dc.contributor.googleauthor | JH Cheon | - |
dc.contributor.googleauthor | SH Choi | - |
dc.identifier.doi | 22068817 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00353 | - |
dc.contributor.localId | A01183 | - |
dc.contributor.localId | A01402 | - |
dc.contributor.localId | A02105 | - |
dc.contributor.localId | A02640 | - |
dc.contributor.localId | A04373 | - |
dc.contributor.localId | A04030 | - |
dc.relation.journalcode | J00406 | - |
dc.identifier.eissn | 1532-1827 | - |
dc.identifier.pmid | 22068817 | - |
dc.subject.keyword | Adenosine Triphosphate/therapeutic use* | - |
dc.subject.keyword | Adult | - |
dc.subject.keyword | Aged | - |
dc.subject.keyword | Antineoplastic Combined Chemotherapy Protocols/therapeutic use* | - |
dc.subject.keyword | Colorectal Neoplasms/drug therapy | - |
dc.subject.keyword | Colorectal Neoplasms/pathology* | - |
dc.subject.keyword | Combined Modality Therapy | - |
dc.subject.keyword | Feasibility Studies | - |
dc.subject.keyword | Female | - |
dc.subject.keyword | Humans | - |
dc.subject.keyword | Liver Neoplasms/drug therapy* | - |
dc.subject.keyword | Liver Neoplasms/secondary | - |
dc.subject.keyword | Liver Neoplasms/surgery | - |
dc.subject.keyword | Male | - |
dc.subject.keyword | Middle Aged | - |
dc.subject.keyword | Treatment Outcome | - |
dc.contributor.alternativeName | Kim, Nam Kyu | - |
dc.contributor.alternativeName | Kim, Ho Keun | - |
dc.contributor.alternativeName | Min, Byung Soh | - |
dc.contributor.alternativeName | Shin, Sang Joon | - |
dc.contributor.alternativeName | Lee, Kang Young | - |
dc.contributor.alternativeName | Cheon, Jae Hee | - |
dc.contributor.alternativeName | Hur, Hyuk | - |
dc.contributor.affiliatedAuthor | Kim, Nam Kyu | - |
dc.contributor.affiliatedAuthor | Kim, Ho Keun | - |
dc.contributor.affiliatedAuthor | Min, Byung Soh | - |
dc.contributor.affiliatedAuthor | Shin, Sang Joon | - |
dc.contributor.affiliatedAuthor | Lee, Kang Young | - |
dc.contributor.affiliatedAuthor | Hur, Hyuk | - |
dc.contributor.affiliatedAuthor | Cheon, Jae Hee | - |
dc.citation.volume | 106 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 53 | - |
dc.citation.endPage | 60 | - |
dc.identifier.bibliographicCitation | BRITISH JOURNAL OF CANCER, Vol.106(1) : 53-60, 2012 | - |
dc.identifier.rimsid | 31927 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.